ReNew Energy Global Plc today announced its unaudited consolidated IFRS results for the three-month period ended September 30, 2025.

Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module ...

CEO Capone announced, "we are reducing our revenue guidance from $21.5 million to $18.5 million," citing decreased BARDA ...

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...